Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
Farren
C K
CK
Department of Psychiatry, Yale University School of Medicine, New Haven, Conn., USA. conor.farren@yale.edu
O'Malley
S S
SS
D000077443:Acamprosate; D000427:Alcohol Deterrents / Q000627:therapeutic use; D000428:Alcohol Drinking / Q000453:epidemiology / Q000523:psychology; D000437:Alcoholism / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D015897:Comorbidity; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D017831:Diagnosis, Dual (Psychiatry); D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013654:Taurine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000077443:Acamprosate; D000427:Alcohol Deterrents; D005473:Fluoxetine; D009271:Naltrexone; D009292:Narcotic Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D013654:Taurine